Zealand Eyes Opportunities In Burgeoning Obesity Market
Boehringer-Partnered Drug Moving Into Phase III Soon
Executive Summary
Given the renewed interest in the commercial potential of obesity therapies, Zealand is heralding the potential of its treatments for the overweight.
You may also be interested in...
Zealand Nabs Novo Nordisk To Save Zegalogue Launch
US approval for its hypoglycemia injection Zegalogue last year has not been converted into commercial success. Zealand will be hoping that having diabetes giant Novo Nordisk onboard will put that right.
Orchard and Zealand Join Growing List Of Biotechs On The Ropes
Orchard and Zealand are the latest European players to succumb to a financial pinch in the biotech sector, streamlining their pipelines and laying off staff to save on expenses.
Zealand Set To Take On Lilly After Zegalogue US Approval
Despite being third to market behind Lilly’s Baqsimi and Xeris’s Gvoke to treat emergency episodes of hypoglycemia, Zealand is confident of a successful US launch for Zegalogue (dasiglucagon).